UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis

Source
Pharmaceutical

The partnership will see Viz.ai develop an AI Care Pathway for cardiac amyloidosis.

Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause of heart failure.

Cardiac amyloidosis is a progressive condition where misfolded proteins accumulate in the heart muscle, often leading to heart failure.

There are two main types of cardiac amyloidosis: wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), and light chain amyloidosis (AL).